Motilium Rx (Domperidone)

Domperidone, the active ingredient in Motilium Rx, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It is employed to improve gastrointestinal motility and to reduce nausea and vomiting in adult patients.

GNH USA supplies Motilium Rx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Motilium Rx acts on peripheral dopamine receptors to address disorders of gastrointestinal motility and emesis. - Nausea and vomiting: alleviates symptoms by enhancing gastric emptying and blocking emetic signals. - Gastroparesis: improves stomach emptying, reducing fullness and bloating. - Functional dyspepsia: relieves upper abdominal discomfort and early satiety. - Post‑operative nausea: prevents nausea after surgical procedures.

Domperidone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Headache: mild to moderate pain often resolving without treatment. - Dizziness: transient light‑headedness, especially when standing quickly. - Abdominal cramps: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, particularly in patients with electrolyte disturbances. - Extrapyramidal symptoms: involuntary muscle movements or tremor. - Galactorrhea: unexpected breast milk production. - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention.

Before prescribing Motilium Rx, clinicians should consider several safety measures. - Cardiac risk assessment: evaluate for existing arrhythmias or QT prolongation. - Concomitant medication review: avoid drugs that also prolong QT interval. - Electrolyte monitoring: correct hypokalemia or hypomagnesemia. - Hepatic impairment caution: adjust use in patients with liver dysfunction. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Domperidone can interact with other medications, affecting safety or efficacy.

Major Interactions (Avoid): - Ketoconazole: potent CYP3A4 inhibition increases domperidone levels. - Quinidine: additive QT‑prolonging effect raises risk of arrhythmia. - Metoclopramide: opposing dopamine actions may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - Rifampicin: CYP3A4 induction may lower domperidone exposure. - Macrolide antibiotics (e.g., erythromycin): may modestly increase plasma concentrations. - Anticholinergic agents: may diminish prokinetic effect. - SSRIs: potential for additive serotonergic side effects.